Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
interferon gamma
- Development stage
- Unknown
- Lead developer
- Pharmaclon
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Intramuscular, Intranasal, Subcutaneous
01
Overview
Ingaron is a recombinant human interferon gamma (IFN-γ) developed by Pharmaclon. It is an immunomodulatory and antiviral cytokine that plays a crucial role in both innate and adaptive immunity. Ingaron is unique in being marketed in Russia in two distinct formulations: an intranasal form (nasal drops) indicated for the prevention and treatment of influenza (including H1N1 and H5N1 strains) and other acute respiratory viral infections (ARVI), and an injectable form (intramuscular or subcutaneous) indicated for the treatment of chronic hepatitis B and C, HIV/AIDS, pulmonary tuberculosis, chronic granulomatous disease, and various oncological conditions (such as renal cell carcinoma, melanoma, breast cancer, and cervical cancer) as an immunomodulator.
- Brand names
- IngaronИнгарон
- Other names
- interferon gammainterferon gamma-1brecombinant human interferon gammarecombinant human interferon-gammaинтерферон гаммаинтерферон гамма человеческий рекомбинантный
02
Targets
IFNGR2 (Interferon gamma receptor 2)IFNGR1 (Interferon gamma receptor 1)
Beyond the preview
Go deeper on interferon gamma.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on interferon gamma.